Advanced Medical Institute (AMI)
Advanced Medical Institute (AMI) owns Intelligent Medical Technologies Pty Limited (IMT). (AMI) has the exclusive worldwide right from Sheiman Ultrasonic Research Foundation Pty Limited (SURF) to exploit and sub-license certain inventions, patents and other intellectual property in relation to certain ultrasonic nebulizer technology (including Australian Patent No's 693064 and 753817, European Patent No's 0 705 145 and 1 071 479 and US Patent No's 5,908,158 and 6,379,616) within the field of the treatment of sexual dysfunction in men and women (including impotence, premature ejaculation and the treatment of female sexual arousal disorders) and the treatment of prostate diseases.
Advanced Medical Institute (AMI), headquartered in Sydney, Australia, is a publicly held Nevada corporation that currently trades on the over-the-counter (bulletin board) market under the symbol AVMD.OB. AMI operates primarily through its wholly-owned Australian subsidiary, AMI Australia. Please click here to access our current corporate structure chart. Advanced Medical Institute (AMI) currently has approximately 53.5 million issued shares.
Advanced Medical Institute (AMI), a leading provider of treatment for Erectile Dysfunction and Premature Ejaculation in Australasia, announces a new not for profit division -- Rocket Launch (www.rocketlaunch.com.au) -- which specialises in providing Erectile Dysfunction advice and treatment programs to men who have sustained a spinal cord injury.
Rocket Launch's trial group of 60 patients delivered a remarkable 100% success rate with all patients capable of gaining and maintaining an erection. With the huge success of their trial, Advanced Medical Institute (AMI) now plans to reach out to the more than 6,000 men in Australia who have sustained a spinal cord injury. Rocket Launch also hopes to assist spinal cord rehabilitation units in hospitals across the country to improve the quality of patient outcomes.
The AMI Australia treatment is offered to men with spinal cord injuries without any initial charge, payment only being requested once the patient has reported success in achieving an erection and wishes to continue with a treatment program with any ongoing charge being on a below cost basis. The work being done is changing the lives of spinal cord injured men who are finding part of their identity and self-esteem is being returned to them by enabling them to be sexually active.
AMI Australia Medical Director and one of Australia's leading urologists, Dr. Lionel Jacobs, explains the reasons for Rocket Launch's efficacy: "There are a number of medications used by Advanced Medical Institute (AMI). These include a method of Nasal Delivery which allows the medication to rapidly and directly enter the patient's bloodstream. This makes the treatment extremely effective and enables a low dosage medication to be utilised. This treatment is also safe for use with most other medications including nitrate-based drugs, which many spinal cord injured patients are prescribed."
AMI nasal Spray developed and patented by the Advanced Medical Institute (AMI) of Australia. AMI are also based in New Zealand and now Europe under amieurope.co.uk. The nasal sprays developed by this company have been under a lot of scrutiny lately and this adds to all the controversy the company as a whole has attracted since its inception in Australia. Advanced Medical Institute (AMI) will now conduct business in the UK through its wholly owned subsidiary, AMI Clinic Limited (AVMD UK).